Literature DB >> 34206223

Society Position Statements on Bio-Identical Hormones-Misinformation Leads to a Dilemma in Women's Health.

Gary S Donovitz1,2.   

Abstract

This commentary reviews the current status of compounding pharmacies and underscores outdated and inaccurate information in the clinical opinions and position statements of two prominent societies.

Entities:  

Keywords:  bio-identical hormones; compounded bio-identical hormones; hormone replacement therapy

Year:  2021        PMID： 34206223     DOI： 10.3390/healthcare9070782

Source DB:  PubMed          Journal:  Healthcare (Basel)        ISSN： 2227-9032


  17 in total

1.  ACOG Committee Opinion No. 387 November 2007: pharmaceutical compounding.

Authors: 
Journal:  Obstet Gynecol       Date:  2007-11       Impact factor: 7.661

2.  Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD.

Authors:  Daniel H S Silverman; Cheri L Geist; Heather A Kenna; Katherine Williams; Tonita Wroolie; Bevin Powers; John Brooks; Natalie L Rasgon
Journal:  Psychoneuroendocrinology       Date:  2010-09-01       Impact factor: 4.905

3.  Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS).

Authors:  Rebecca Glaser; Anne E York; Constantine Dimitrakakis
Journal:  Maturitas       Date:  2010-12-21       Impact factor: 4.342

4.  The effects of subcutaneous hormone implants during climacteric.

Authors:  L Cardozo; D M Gibb; S M Tuck; M H Thom; J W Studd; D J Cooper
Journal:  Maturitas       Date:  1984-03       Impact factor: 4.342

5.  The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years.

Authors:  Philip M Sarrel; Valentine Y Njike; Valentina Vinante; David L Katz
Journal:  Am J Public Health       Date:  2013-07-18       Impact factor: 9.308

6.  Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause.

Authors:  B B Sherwin; M M Gelfand
Journal:  Am J Obstet Gynecol       Date:  1984-03-01       Impact factor: 8.661

7.  Compounded bioidentical menopausal hormone therapy.

Authors: 
Journal:  Fertil Steril       Date:  2012-08       Impact factor: 7.329

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study.

Authors:  Gary Donovitz; Mandy Cotten
Journal:  Eur J Breast Health       Date:  2021-03-31

10.  The 2017 hormone therapy position statement of The North American Menopause Society.

Authors: 
Journal:  Menopause       Date:  2017-07       Impact factor: 3.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.